Taxotere Lawsuit Update
Taxotere is a microtubule inhibitor prescribed to treat treat breast, lung, prostate, stomach, and head and neck cancer. However, it has certain serious side effects that its manufacturer, Sanofi, might not have adequately warned patients of. Litigation is ongoing, and this Taxotere lawsuit update page will keep you informed on the latest developments.
Have you experienced health problems as a result of a Taxotere prescription? Then visit our case evaluation test to find out if you Sanofi might owe you money.
Taxotere Lawsuit Update – August 2023
A study featured in the Journal of JAMA Ophthalmology backs up claims made by plaintiffs, suggesting that Taxotere may lead to optic neuropathy, cystoid macular edema (CME), and excessive tearing (epiphora), as the drug intensified watery eyes by a factor of seven.
While Sanofi maintains that an eye injury warning was incorporated into the label in 2002, attorneys representing the plaintiffs assert that the label failed to sufficiently caution about the potential for permanent tear duct injury caused by the drug.
Taxotere Lawsuit Update – June 2023
Sanofi-Aventis is currently entangled in tens of thousands of Taxotere lawsuits in the hair loss MDL. The company achieved initial victories in bellwether lawsuits in 2019 and 2021. Still, in February 2022, Sanofi experienced a setback as the 5th U.S. Circuit Court of Appeals Judge Cory Wilson, overturned the verdict of the first bellwether case on appeal.
In February 2023, Sanofi secured yet another victory in a bellwether trial. However, the date for the third trial remains undecided. As the Taxotere hair loss lawsuits continue in the bellwether phase, the timeline for the MDL could take up to a year to be established.